Compare IKT & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IKT | BCIC |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.9M | 159.5M |
| IPO Year | 2020 | N/A |
| Metric | IKT | BCIC |
|---|---|---|
| Price | $1.66 | $11.81 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 499.5K | 81.5K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 16.11% |
| EPS Growth | N/A | ★ 330.32 |
| EPS | N/A | ★ 1.64 |
| Revenue | N/A | ★ $58,080,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.00 |
| P/E Ratio | ★ N/A | $7.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $11.12 |
| 52 Week High | $3.49 | $17.51 |
| Indicator | IKT | BCIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.62 | N/A |
| Support Level | $1.52 | N/A |
| Resistance Level | $1.67 | N/A |
| Average True Range (ATR) | 0.11 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.91 | 0.00 |
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.